Amgen : Announces New Lumakras™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021

THOUSAND OAKS, Calif. , Oct. 7, 2021 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy of LUMAKRAS™ (sotorasib), the first and only approved KRAS G12C inhibitor, in more than 10 different investigational combination regimens for the treatment of patients with KRAS G12C-mutated cancers.

Read the source article at Stock Market Quotes and News
2021-10-07 14:01:15